Stay updated on Pembrolizumab in NSCLC with PS 2 Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.

Latest updates to the Pembrolizumab in NSCLC with PS 2 Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added. The earlier notice Revision: v3.4.1 and related government funding/operating status notices were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about government funding status and a new revision tag (v3.4.1) were added, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedUI and metadata updates include showing the glossary and adding the QC-related label 'Last Update Submitted that Met QC Criteria' and the revision tag 'Revision: v3.4.0'. The earlier QC label, 'No FEAR Act data,' and 'Revision: v3.3.4' text are removed or updated accordingly.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded new study locations: Greater Manchester, Hampshire, Kent, and West Midlands, with the page revision updated to v3.3.3.SummaryDifference0.5%

- Check92 days agoChange DetectedMinor wording update in the Publications section: 'These publications are provided voluntarily by the person who enters information about the study and are about the results of the study' was changed to improve grammar (Revision: v3.2.0 → v3.3.2); to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in NSCLC with PS 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.